Rivastigmine For Methamphetamine Dependent Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00158210|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Substance-Related Disorders||Drug: Rivastigmine||Phase 1|
Methamphetamine is a powerful stimulant that affects the central nervous system. Chronic methamphetamine use often leads to psychotic behavior. Rivastigmine is an acetylcholinesterase inhibitor that is currently approved to treat Alzheimer's-related dementia. The purpose of this study is to assess the efficacy of rivastigmine in treating methamphetamine dependent individuals.
Participants will be randomly assigned to either one of two dose levels of rivastigmine or placebo for 12 weeks. Participants will be assessed for cardiovascular, subjective, and reinforcing effects that are produced by methamphetamine. All participants will partake in contingency management sessions through Week 4.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Double-Blind Randomized Placebo Controlled Trial of Rivastigmine (Excelon) as a Potential Medication for Methamphetamine Abuse|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||March 2007|
|Actual Study Completion Date :||March 2007|
- Methamphetamine abstinence
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00158210
|United States, California|
|University of California - Los Angeles|
|Los Angeles, California, United States, 90024|
|Principal Investigator:||Steve Shoptaw, PhD||University of California, Los Angeles|